Abstract
Inflammation has recently been implicated as a critical mechanism in Alzheimer’s disease (AD). Microglia are the resident immune cells in the central nervous system (CNS), and they mediate the inflammatory response in the AD brain. Thus, suppression of microglial activation and subsequent neuroinflammation may be a potential therapeutic approach against AD. In the following review, we briefly discuss the limitations and advantages of current drug targets for AD and then summarize several anti-inflammatory drugs in trial, including natural nonsteroidal anti-inflammatory drugs (NSAIDs), polyphenols and new drugs synthesized based on multi-target directed ligand (MTDL) design. In addition to their anti-inflammatory effects, these drugs can act as anti-oxidants and reduce microglial activation or amyloid-β (Aβ) plaques. Thus, the studies focused on multiple factors in AD processes might reveal the best potential treatment strategy for the future.
Keywords: Alzheimer’s disease, anti-inflammatory drugs, microglia, MTDL, NSAIDs, polyphenols.
Current Medicinal Chemistry
Title:The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer’s Disease
Volume: 20 Issue: 20
Author(s): S. Shi, Z. Wang and Z. Qiao
Affiliation:
- School of Life Science and Biotechnology, Shanghai Jiao Tong University, 800 Dongchuan Road 200240 Shanghai, P. R. China.,China
Keywords: Alzheimer’s disease, anti-inflammatory drugs, microglia, MTDL, NSAIDs, polyphenols.
Abstract: Inflammation has recently been implicated as a critical mechanism in Alzheimer’s disease (AD). Microglia are the resident immune cells in the central nervous system (CNS), and they mediate the inflammatory response in the AD brain. Thus, suppression of microglial activation and subsequent neuroinflammation may be a potential therapeutic approach against AD. In the following review, we briefly discuss the limitations and advantages of current drug targets for AD and then summarize several anti-inflammatory drugs in trial, including natural nonsteroidal anti-inflammatory drugs (NSAIDs), polyphenols and new drugs synthesized based on multi-target directed ligand (MTDL) design. In addition to their anti-inflammatory effects, these drugs can act as anti-oxidants and reduce microglial activation or amyloid-β (Aβ) plaques. Thus, the studies focused on multiple factors in AD processes might reveal the best potential treatment strategy for the future.
Export Options
About this article
Cite this article as:
Shi S., Wang Z. and Qiao Z., The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer’s Disease, Current Medicinal Chemistry 2013; 20(20) . https://dx.doi.org/10.2174/0929867311320200006
DOI https://dx.doi.org/10.2174/0929867311320200006 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Preface
Current Molecular Medicine Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Infectious Etiology of Alzheimer’s Disease
Current Neuropharmacology Preface [Hot Topic: Advances in the Four Pillars of Alzheimer Disease Research: Pathobiology, Genetics, Diagnosis, and Treatment (Debomoy K. Lahiri)]
Current Alzheimer Research Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology The Endocannabinoid System in Parkinsons Disease
Current Pharmaceutical Design Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer’s Disease Patients?
CNS & Neurological Disorders - Drug Targets Enhanced Hyperthermia Induced by MDMA in Parkin Knockout Mice
Current Neuropharmacology Calcium-Sensing Receptors of Human Astrocyte-Neuron Teams: Amyloid-β-Driven Mediators and Therapeutic Targets of Alzheimer's Disease
Current Neuropharmacology Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Potential Replication of Induced Pluripotent Stem Cells for Craniofacial Reconstruction
Current Stem Cell Research & Therapy Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Scope and Limitations of The Co-Drug Approach to Topical Drug Delivery
Current Pharmaceutical Design Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Mitochondria: Prospective Targets for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Advances in Stem Cells Transplantation for the Therapy of Parkinson’s Disease
Current Stem Cell Research & Therapy Anti-IL-1 β Therapies
Recent Patents on DNA & Gene Sequences Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential
Current Aging Science